Participated · Series B · Aug 2026

BEI develops and manufactures anode-free lithium metal batteries designed for high energy density and power; its current-generation cells exceed 500 Wh/kg according to the company. Independent testing by About:Energy confirmed leading energy density and power characteristics, and a BEI-powered drone demonstrated over 30 minutes of flight at −26°C during a field demo in Finland. BEI reports more than 30 global UAV customers are evaluating or deploying its cells, which are already integrated into operational small unmanned systems. The company is commercially shipping its AFLMB cells today while advancing a roadmap targeting future cell generations with energy densities above 600 Wh/kg. With the Series B proceeds, BEI plans to scale manufacturing, run customer qualification programs, and expand commercially across Korea, the U.S., and Europe. Strategic partnerships and investor relationships aim to strengthen supply-chain resilience and support adoption in defense, robotics, and electric mobility markets.

Participated · Seed · May 2026

Asteromorph develops a foundation model, Spacer, that it says combines a base LLM with deep domain knowledge and multi-step reasoning to autonomously generate research ideas and scientific hypotheses in biology and chemistry. Its flagship initiative, the "Library Project," aims to run the autonomous system at scale to uncover fundamental mechanisms of life and compile findings into a structured database. The company emphasizes autonomous hypothesis generation and end-to-end scientific workflows rather than solely assisting human researchers. Leadership includes CEO Lee Min-hyung, who entered advanced research training early, and a core team of young researchers from top Korean STEM programs. Financially, Asteromorph has raised a $31.4M seed round and previously raised approximately ₩5 billion. The company faces the challenge of validating model-generated discoveries through rigorous experimental work at scale.

Led · Series C · Apr 2026

Mediwhale develops AI-driven retinal imaging analysis tools that predict cardiovascular risk from a single eye image, marketed under names including Dr. Noon CVD. The company is focused on commercializing those AI biomarkers and expanding partnerships with imaging hardware vendors such as iCare. Mediwhale is actively pursuing FDA De Novo clearance to access the U.S. market and has publicly stated plans to prepare for a public listing, targeting KOSDAQ in 2027 while positioning for a broader U.S. listing narrative. Financially, the firm has raised roughly ₩51.2 billion (about $34M) to date, most recently securing ₩20 billion in a Series C. The company emphasizes scaling global commercialization and regulatory readiness as near-term priorities.

Participated · Series C · Apr 2026

Founded in 2020 and headquartered in South Korea, Upstage builds large language models (including its SOLAR LLM) and a document processing solution called Document PATH. Its product suite focuses on converting unstructured data into actionable insights through document parsing and information extraction to automate enterprise workflows. The company targets industries such as insurance, healthcare, and finance. Following the Series C, Upstage achieved a valuation above 1 trillion won and plans to expand GPU infrastructure and hire global AI talent. It also intends to scale operations internationally, particularly across the U.S. and Japan. The article did not disclose revenue, user counts, or other operating metrics.

Participated · Series C · Mar 2026

MustBio develops next-generation immuno-oncology therapies using a multi-antibody platform called BICSTA and a tumor-selective immunocytokine platform called STARKINE. The company is advancing a portfolio of tri-specific fusion immuno-oncology candidates, with lead programs including MB5 (an IL-2–based therapeutic in clinical development) and MB7 (an IL-21–based program in R&D). Since its founding in 2021, MustBio has raised a total of 635억원 across prior rounds and the recent Series C. The firm has entered collaboration and licensing arrangements with Celltrion and was selected for JLABS Korea and the Seoul BioHub open innovation programs. Proceeds from the Series C are earmarked to accelerate MB5 clinical work, advance MB7 R&D, expand the pipeline, and support global business development and potential technology licensing. Management has stated plans to pursue additional tri-specific antibody R&D and broaden global partnerships.